Piramal Pharma Expects Strong FY27 Growth Driven by Business Momentum
Piramal Pharma expects to maintain mid-teen revenue growth in FY27 and achieve a significant improvement in profitability, supported by strong demand across its businesses and improved operational efficiency. Chairperson Nandini Piramal said the company will continue to focus on organic expansion rather than acquisitions as it builds long-term growth. The company reported a strong performance…
